期刊文献+

α/β干扰素通过上调SARI表达抑制淋巴瘤细胞的增殖 被引量:4

Interferon-α/β inhibits lymphoma cell proliferation by up-regulating SARI expression
原文传递
导出
摘要 目的初步探讨α/β干扰素抑制淋巴瘤细胞增殖的分子机制。方法用IFN-α/β处理淋巴瘤细胞(Namalwa、JeKo-1)和白血病细胞(Jurkat、THP-1)24 h,CCK-8法检测IFN-α/β对上述细胞的增殖抑制效果;RT-PCR、real-time PCR、Western blot检测其SARI mRNA和蛋白水平的变化;对SARI基因启动子区的转录因子结合位点进行生物信息学预测。结果 IFN-α和IFN-β均可有效杀伤Namalwa和JeKo-1淋巴瘤细胞(P<0.05),且均能显著诱导淋巴瘤细胞SARI mRNA和蛋白的表达(P<0.05),但两种干扰素对Jurkat和THP-1白血病细胞的存活及SARI的表达均无显著影响(P>0.05);生物信息学分析显示,SARI启动子区含有转录因子STAT的结合位点。结论上调SARI表达可能是IFN-α/β抑制淋巴瘤细胞增殖的机制之一,而SARI的上调可能是由STAT介导的。 Objective To investigate the mechanism of interferon-α/β (IFN-α/β) inhibiting lymphoma cell proliferation. Methods Lymphoma cells (Namalwa and JeKo-1 ) and leukemia cells (Jurkat and THP-1 ) were treated with IFN-α/β for 24 h. Cell viability was measured by CCK-8 assay. The mRNA and protein expression levels of SARI were detected by reverse transcription PCR, real-time PCR and Western blotting. The transcription factor binding sites in SARI gene promoter region were predicted using bioinformatics method. Results Lymphoma cells (Namalwa and JeKo-1 ) were effectively killed by both IFN-α and IFN-β ( P 〈 0. 05 ), and the mRNA and protein expression levels of SARI were significantly up-regulated ( P 〈 0.05 ). However, IFN-α/β had no significant effect on cell viability and SARI expression of leukemia cells (Jurkat and THP-1 ) (P 〉 0.05 ). Bioinformatics results revealed that transcription factor STAT might bind to SARI gene promoter region. Conclusion Upregulation of SARI, which is possibly mediated by STAT, may be involved in the process of IFN-α/β inhibiting lymphoma cell proliferation.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2012年第24期2465-2468,共4页 Journal of Third Military Medical University
基金 国家自然科学基金(30900642) 重庆市自然科学基金(CSTC2011JJA10015) 第三军医大学校管课题(2009XQN07)~~
关键词 干扰素 SARI 淋巴瘤 STAT interferon SARI lymphoma STAT
  • 相关文献

参考文献23

  • 1Tenoever B R, Ng S L, Chua M A, ei al. Multiple functions of theIKK-related kinase IKKepsilon in interferon-mediated antiviral immuni-ty[J]. Science, 2007,315(5816): 1274 -1278.
  • 2Williams R F,Sims T L,Tracey L, et al. Maturation of tumor vascula-ture by interferon-beta disrupts the vascular niche of glioma stem cells[J]. Anticancer Res, 2010,30(9) : 3301 -3308.
  • 3Patel J N,Walko C M. Sylatron: a pegylated interferon for use in mel-anoma[ J]. Ann Pharmacother, 2012, 46(6) : 830 -838.
  • 4Blasi M A, Tiberti A C, Valente P, et al. Intralesional interferon-al-pha for conjunctival mucosa-associated lymphoid tissue lymphoma :long-term resultsf J]. Ophthalmology, 2012, 119(3) : 494-500.
  • 5Itonaga H, Tsushima H, Hata T, et al. Successful treatment of a chro-nic-phase T-315I-mutated chronic myelogenous leukemia patient with acombination of imatinib and interferon-alfa [ J]. Int J Hematol, 2012,95(2): 209 -213.
  • 6Bekisz J, Baron S, Balinsky C, et al. Antiproliferative Properties ofType I and Type II Interferon[ J]. Pharmaceuticals (Basel), 2010, 3(4): 994-1015.
  • 7Sarkar D, Park E S,Fisher P B. Defining the mechanism by whichIFN-beta dowregulates c-myc expression in human melanoma cells : piv-otal role for human polynucleotide phosphorylase ( hPNPaseold-35 )[J]. Cell Death Differ, 2006, 13(9) : 1541 -1553.
  • 8Takada E, Shimo K, Hata K, et al. Interferon-beta-induced activationof c-Jun NH2-terminal kinase mediates apoptosis through up-regulationof CD95 in CH31 B lymphoma cells [ J]. Exp Cell Res, 2005,304(2): 518 -530.
  • 9Su Z Z,Lee S G,Emdad L,et al. Cloning and characterization of SA-RI (suppressor of AP-1,regulated by IFN) [ J] . Proc Natl Acad Sci US A, 2008, 105(52): 20906 - 20911.
  • 10Ma H,Liang X, Chen Y, et al. Decreased expression of BATF2 isassociated with a poor prognosis in hepatocellular carcinoma[ J] . Int JCancer, 2011,128(4) : 771 -777.

二级参考文献26

  • 1Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer [ J ]. Hum Mutat, 2006, 27 ( 1 ) : 110-117.
  • 2Hassler M, Singh S, Yue W W, et al. Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction, and holoprotein architecture [J]. MolCell, 2007, 28(3): 371-385.
  • 3Beg A A, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death [ J]. Science, 1996, 274(5288) : 782-784.
  • 4Hayden M S, Ghosh S. Signaling to NF-kappaB [ J]. Genes Dev, 2004, 18(18) : 2195-2224.
  • 5Liu Z G, Hsu H, Goeddel D V, et al. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death [ J ]. Cell, 1996, 87(3) : 565-576.
  • 6Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle [J]. Cell, 2002, 109(Suppl) : $81-$96.
  • 7Karin M, Greten F R. NF-kappaB: linking inflammation and immunity to cancer development and progression [ J]. Nat Rev Immunol, 2005, 5( 10): 749-759.
  • 8Shishodia S, Aggarwal B B. Nuclear factor-kappaB : a friend or a foe in cancer? [J]. Biochem Pharmacol, 2004, 68(6) : 1071- 1080.
  • 9Meylan E, Dooley A L, Feldser D M, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma [J]. Nature, 2009, 462(7269): 104-107.
  • 10Huang W C, Ju T K, Hung M C, et al. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB [ J]. Mol Cell, 2007, 26(1) : 75-87.

共引文献13

同被引文献31

  • 1Su Z Z, Lee S G, Emdad L, et al. Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN) [J]. Proc Natl Acad Sci U S A, 2008, 105(52): 20906-20911.DOI:10.1073/pnas.0807975106.
  • 2Dorsey M J, Tae H J, Sollenberger K G, et al. B-ATF: a novel human bZIP protein that associates with members of the AP-1 transcription factor family[J]. Oncogene, 1995, 11(11): 2255-2265.
  • 3Dash R, Su Z Z, Lee S G, et al. Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1[J]. Oncogene, 2010, 29(31): 4412-4423. DOI:10.1038/onc.2010.194.
  • 4Ma H, Liang X, Chen Y, et al. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma[J]. Int J Cancer, 2011, 128(4): 771-777. DOI:10.1002/ijc.25407.
  • 5Wang C, Su Y, Zhang L, et al. The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis[J]. PLoS One, 2012, 7(9): e38046. DOI:10.1371/journal.pone.0038046.
  • 6Wen H, Chen Y, Hu Z, et al. Decreased expression of BATF2 is significantly associated with poor prognosis in oral tongue squamous cell carcinoma[J]. Oncol Rep, 2014, 31(1): 169-174. DOI:10.3892/or.2013.2863.
  • 7Liu Z, Wei P, Yang Y, et al. BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs[J]. Clin Cancer Res, 2015, 21(7): 1752-1763. DOI:10.1158/1078-0432.CCR-14-1564.
  • 8Meggiato T, Calabrese F, De-Cesare C M, et al. C-JUN and CPP32 (CASPASE 3) in human pancreatic cancer: relation to cell proliferation and death[J]. Pancreas, 2003, 26(1): 65-70.
  • 9Echlin D R, Tae H J, Mitin N, et al. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos[J]. Oncogene, 2000, 19(14): 1752-1763. DOI:10.1038/sj.onc.1203491.
  • 10Yen J H, Kocieda V P, Jing H, et al. Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation[J]. J Biol Chem, 2011, 286(45): 38913-38923. DOI:10.1074/jbc.M111.252932.

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部